GLT8D1 promotes glioma progression by stabilizing CD133 via hypoxia-induced N-linked glycosylation, thereby supporting glioma stem cell maintenance and activating Wnt/β-catenin–dependent tumor growth; its elevated expression is closely associated with higher tumor grade and poor prognosis, underscoring its potential as a therapeutic target (44, 48). The gene discussed is GLT8D1; the disease is central nervous system cancer.